Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial'

Foundayo hits MACE-4 non-inferiority (HR 0.84) as Lillytargets diabetes filing by Q2 — but FDA requests liver risk data. Plus: Cochrane review dismisses anti-amyloid Alzheimer's drugs, Daiichi Sankyo divests $1.5B consumer health unit, and Kailera's $533M obesity IPO pricesahead of tomorrow's trading.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Foundayo,orforglipron, Eli Lilly, GLP-1, obesity, diabetes, ACHIEVE-4, MACE, Cochrane,Alzheimer's, lecanemab, donanemab, anti-amyloid, Kailera Therapeutics, IPO,Daiichi Sankyo, Suntory, Roche, Elevidys, Sarepta, Duchenne, RevolutionMedicines, Obsidian Therapeutics, CrossBridge Bio, ADC, UnitedHealth, Lilly,Novo Nordisk, AstraZeneca, Biogen